Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.

ABSTRACT: Through antigenic drift and shifts, influenza virus infections continue to be an annual cause of morbidity in healthy populations and of death among elderly and at-risk patients. The emergence of highly pathogenic avian influenza viruses such as H5N1 and H7N9 and the rapid spread of the swine-origin H1N1 influenza virus in 2009 demonstrate the continued need for effective therapeutic agents for influenza. While several neuraminidase inhibitors have been developed for the treatment of influenza virus infections, these have shown a limited window for treatment initiation, and resistant variants have been noted in the population. In addition, an older class of antiviral drugs for influenza, the adamantanes, are no longer recommended for treatment due to widespread resistance. There remains a

SUBMITTER: Tsai AW 

PROVIDER: S-EPMC4576026 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature